Boston Scientific Earlier Disclosed That On Apr. 3, Co. And Axonics Received Request For Additional Information From FTC In Connection With FTC's Merger Review; Says The Merger Is Now Expected To Be Completed In The Second Half Of 2024

4/4/24 8:55:38 AM ET

$AXNX

$BSX

Medical/Dental Instruments

Health Care

Medical/Dental Instruments

Health Care

Get the next $AXNX alert in real time by email

Boston Scientific Earlier Disclosed That On Apr. 3, Co. And Axonics Received Request For Additional Information From FTC In Connection With FTC's Merger Review; Says The Merger Is Now Expected To Be Completed In The Second Half Of 2024

Get the next $AXNX alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$AXNX
$BSX

Company	Date	Price Target	Rating	Analyst
Boston Scientific Corporation $BSX	10/18/2024		Buy → Hold	Needham
Boston Scientific Corporation $BSX	5/30/2024	$90.00	Buy	Goldman
Boston Scientific Corporation $BSX	2/1/2024	$65.00 → $80.00	Neutral → Buy	Mizuho
Axonics Inc. $AXNX	1/9/2024		Outperform → Peer Perform	Wolfe Research
Boston Scientific Corporation $BSX	7/19/2023	$59.00	Outperform	Robert W. Baird
Axonics Inc. $AXNX	7/19/2023	$69.00	Outperform	Robert W. Baird
Axonics Inc. $AXNX	7/13/2023	$70.00	Overweight	KeyBanc Capital Markets
Boston Scientific Corporation $BSX	6/30/2023	$64.00	Buy	CL King

More analyst ratings

$AXNX
$BSX
Press Releases

Fastest customizable press release news feed in the world

Boston Scientific to Participate in the 2024 UBS Global Healthcare Conference
MARLBOROUGH, Mass., Nov. 5, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) will participate in the 2024 UBS Global Healthcare Conference on Tuesday, November 12, 2024. Nick Spadea-Anello, president, Electrophysiology, and Jon Monson, senior vice president, Investor Relations, will participate in a 35-minute question-and-answer session with the host analyst at approximately 7:15 a.m. PT / 10:15 a.m. ET. A live webcast and replay of the session will be accessible at htts://investors.bostonscientific.com. The replay will be available approximately one hour followin
11/5/24 8:00:00 AM ET
$BSX
Medical/Dental Instruments
Health Care
Boston Scientific Announces Agreement to Acquire Cortex, Inc.
Acquisition to complement electrophysiology portfolio with solution to advance the treatment of complex atrial fibrillation MARLBOROUGH, Mass., Nov. 4, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) today announced it has entered into a definitive agreement to acquire Cortex, Inc., an Ajax Health company. Cortex is a privately held medical technology company focused on the development of a diagnostic mapping solution which may identify triggers and drivers outside of the pulmonary veins that are foundational to atrial fibrillation (AF), a heart rhythm disorder affecting nearly 38 million people globally.1
11/4/24 6:55:00 AM ET
$BSX
Medical/Dental Instruments
Health Care
ACURATE neo2™ Aortic Valve System Data Presented at Late-Breaking Clinical Trial Session at TCT 2024
MARLBOROUGH, Mass. and WASHINGTON, Oct. 30, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) today announced the results of the primary endpoint of the ACURATE IDE clinical trial, which evaluated the ACURATE neo2™ Aortic Valve System in the treatment of patients with severe, symptomatic aortic stenosis at low, intermediate, high and extreme risk of open-heart surgery. The data were presented as a late-breaking clinical trial at Transcatheter Cardiovascular Therapeutics® (TCT®) 2024, the annual scientific symposium of the Cardiovascular Research Foundation® (CRF®).
10/30/24 11:41:00 AM ET
$BSX
Medical/Dental Instruments
Health Care

$AXNX
$BSX
Leadership Updates

Live Leadership Updates

Kestra Medical Technologies Announces Appointment of Veteran Medical Device Executive, Raymond W. Cohen, to its Board of Directors
Kestra Medical Technologies, Inc., a privately held wearable medical device and digital healthcare company, today announced that Raymond W. Cohen has joined the board of directors as a new independent board director. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240725221367/en/Kestra Medical Technologies, Inc. announced that Raymond W. Cohen has joined the board of directors as a new independent board director. (Photo: Business Wire) Brian Webster, President & CEO of Kestra said, "Ray is one of the most experienced and accomplished leaders in the medical device industry with multiple decades of success in developing and commer
7/25/24 8:00:00 AM ET
$AXNX
Medical/Dental Instruments
Health Care
BiVACOR Appoints Veteran Medical Device Executive Raymond W. Cohen as Chairman of the Board of Directors
BiVACOR, Inc., a clinical-stage medical technology company developing a total artificial heart (TAH), today announced that Raymond W. Cohen has been appointed chairman of its board of directors. Mr. Cohen is an accredited public company director with over 40 years of experience in the life sciences industry. He currently serves as chief executive officer and member of the board of directors of Axonics, Inc. (NASDAQ:AXNX), an Irvine, Calif. based global medical technology company that he co-founded in 2013 and took public in October 2018. Axonics ranked No. 1 on the 2021 Deloitte Technology Fast 500™ and the 2022 Financial Times ranking of the 500 fastest growing companies in the Americas.
12/27/23 8:00:00 AM ET
$AXNX
Medical/Dental Instruments
Health Care
CVS Health appoints Michael F. Mahoney to its Board of Directors
WOONSOCKET, R.I., Sept. 21, 2023 /PRNewswire/ -- CVS Health Corporation (NYSE:CVS) has appointed Michael F. Mahoney, Chairman and CEO of Boston Scientific Corporation (NYSE:BSX), a global medical technology leader, to serve on the Board of Directors (the "Board") of CVS Health, effective November 1. "Mike's focus throughout his career – to drive improvements in health outcomes and increase access to care – align with our mission at CVS Health," said CVS Health President and CEO Karen S. Lynch. "Adding a well-respected health care leader to our Board demonstrates our continued
9/21/23 6:45:00 AM ET
$BSX
$CVS
Medical/Dental Instruments
Health Care
Retail-Drug Stores and Proprietary Stores
Consumer Staples

$AXNX
$BSX
Financials

Live finance-specific insights

Boston Scientific Announces Results for Third Quarter 2024
MARLBOROUGH, Mass., Oct. 23, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $4.209 billion during the third quarter of 2024, growing 19.4 percent on a reported basis, 19.5 percent on an operational1 basis and 18.2 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $469 million or $0.32 per share (EPS), compared to $505 million or $0.34 per share a year ago, and achieved adjusted3 EPS of $0.63 for the period, compared to $0.50 a year ago.
10/23/24 6:30:00 AM ET
$BSX
$SILK
Medical/Dental Instruments
Health Care
Boston Scientific Announces Conference Call Discussing Third Quarter 2024 Results
-Company to also host virtual webcast with a cardiology business update- MARLBOROUGH, Mass., Oct. 2, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) will webcast its conference call discussing financial results and business highlights for the third quarter ended September 30, 2024, on Wednesday, October 23, 2024, at 8:00 a.m. ET. The call will be hosted by Mike Mahoney, chairman and chief executive officer, and Dan Brennan, executive vice president and chief financial officer. The company will issue a news release announcing financial results for the third quarter on October 23 prior to the conference call.
10/2/24 8:00:00 AM ET
$BSX
Medical/Dental Instruments
Health Care
Boston Scientific Announces Results for Second Quarter 2024
MARLBOROUGH, Mass., July 24, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) generated net sales of $4.120 billion during the second quarter of 2024, growing 14.5 percent on a reported basis, 16.1 percent on an operational1 basis and 14.7 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $324 million or $0.22 per share (EPS), compared to $261 million or $0.18 per share a year ago, and achieved adjusted3 EPS of $0.62 for the period, compared to $0.53 a year ago.
7/24/24 6:30:00 AM ET
$BSX
$SILK
Medical/Dental Instruments
Health Care

Boston Scientific Earlier Disclosed That On Apr. 3, Co. And Axonics Received Request For Additional Information From FTC In Connection With FTC's Merger Review; Says The Merger Is Now Expected To Be Completed In The Second Half Of 2024

Chat with this insight

Recent Analyst Ratings for $AXNX$BSX

$AXNX$BSX Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

EVP, Human Resources Carruthers Wendy sold $588,876 worth of shares (6,983 units at $84.33) and exercised 4,263 shares at a strike of $19.31, decreasing direct ownership by 8% to 32,028 units (SEC Form 4)

EVP & Group Pres, Cardiology Fitzgerald Joseph Michael exercised 116,639 shares at a strike of $21.07 and sold $11,264,888 worth of shares (132,527 units at $85.00), decreasing direct ownership by 9% to 160,467 units (SEC Form 4)

Chairman, President & CEO Mahoney Michael F exercised 111,886 shares at a strike of $16.79 and sold $13,775,792 worth of shares (162,777 units at $84.63), decreasing direct ownership by 3% to 1,572,096 units (SEC Form 4)

$AXNX$BSX Press Releases

Fastest customizable press release news feed in the world

Boston Scientific to Participate in the 2024 UBS Global Healthcare Conference

Boston Scientific Announces Agreement to Acquire Cortex, Inc.

ACURATE neo2™ Aortic Valve System Data Presented at Late-Breaking Clinical Trial Session at TCT 2024

$AXNX$BSX SEC Filings

SEC Form 10-Q filed by Boston Scientific Corporation

Boston Scientific Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

SEC Form 10-Q filed by Boston Scientific Corporation

$AXNX$BSX Market Insights

Live Market Insights

$AXNX$BSX Large Ownership Changes

This live feed shows all institutional transactions in real time.

Apple To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Thursday

JP Morgan Maintains Overweight on Boston Scientific, Raises Price Target to $85

Canaccord Genuity Maintains Buy on Boston Scientific, Raises Price Target to $88

SEC Form SC 13G/A filed by Boston Scientific Corporation (Amendment)

SEC Form SC 13G/A filed by Axonics Inc. (Amendment)

SEC Form SC 13G/A filed by Axonics Inc. (Amendment)

$AXNX$BSX Leadership Updates

Live Leadership Updates

Kestra Medical Technologies Announces Appointment of Veteran Medical Device Executive, Raymond W. Cohen, to its Board of Directors

BiVACOR Appoints Veteran Medical Device Executive Raymond W. Cohen as Chairman of the Board of Directors

CVS Health appoints Michael F. Mahoney to its Board of Directors

$AXNX$BSX FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

March 1, 2024 - FDA Roundup: March 1, 2024

$AXNX$BSX Financials

Live finance-specific insights

Boston Scientific Announces Results for Third Quarter 2024

Boston Scientific Announces Conference Call Discussing Third Quarter 2024 Results

Boston Scientific Announces Results for Second Quarter 2024

$AXNX$BSX Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Boston Scientific downgraded by Needham

Goldman initiated coverage on Boston Scientific with a new price target

Boston Scientific upgraded by Mizuho with a new price target

Recent Analyst Ratings for
$AXNX
$BSX

$AXNX
$BSX
Insider Trading

$AXNX
$BSX
Press Releases

$AXNX
$BSX
SEC Filings

$AXNX
$BSX
Market Insights

$AXNX
$BSX
Large Ownership Changes

$AXNX
$BSX
Leadership Updates

$AXNX
$BSX
FDA approvals

$AXNX
$BSX
Financials

$AXNX
$BSX
Analyst Ratings